Financial Performance - The company's operating revenue for Q3 2024 was CNY 2,236,724,325.90, a decrease of 0.32% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was CNY 132,739,308.31, an increase of 10.65% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date was CNY 607,069,625.40, reflecting a 9.36% increase compared to the previous year[6]. - The basic earnings per share for Q3 2024 was CNY 0.18, down 30.77% from the same period last year[3]. - Total operating revenue for the first three quarters of 2024 reached ¥7,423,276,804.99, an increase from ¥7,316,820,996.26 in the same period of 2023, representing a growth of approximately 1.46%[16]. - Net profit for the first three quarters of 2024 was ¥633,953,374.65, up from ¥605,785,162.05 in 2023, reflecting a growth of approximately 4.73%[18]. - Total comprehensive income for the period reached CNY 634,016,268.78, an increase from CNY 605,785,162.05 in the previous year[19]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,389,220,215.01, a decrease of 1.29% from the end of the previous year[3]. - The company's total assets as of the end of the third quarter of 2024 were ¥15,389,220,215.01, a decrease from ¥15,590,329,775.23 at the end of the previous quarter[14]. - The total liabilities decreased to ¥7,486,663,182.91 from ¥7,870,494,104.65, showing a reduction of about 4.87%[14]. - The total equity attributable to shareholders at the end of the reporting period was CNY 7,485,939,780.05, an increase of 2.29% from the previous year[3]. - The equity attributable to shareholders of the parent company increased to ¥7,485,939,780.05 from ¥7,318,625,200.44, marking an increase of approximately 2.28%[15]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY -36,159,027.91, a significant decrease of 112.56% compared to the previous year[6]. - Cash inflow from operating activities totaled CNY 7,182,115,065.89, down from CNY 7,667,040,813.17 year-over-year[20]. - Cash outflow for operating activities was CNY 7,218,274,093.80, compared to CNY 7,379,098,391.22 in the previous year[21]. - Net cash flow from investing activities was CNY -263,629,923.83, an improvement from CNY -436,548,699.42 in the previous year[21]. - Cash flow from financing activities resulted in a net outflow of CNY -392,846,564.74, compared to a net inflow of CNY 940,311,207.02 in the same period last year[21]. - The ending balance of cash and cash equivalents was CNY 2,348,299,423.67, up from CNY 2,250,312,516.61 year-over-year[21]. - The company received CNY 774,990,000.00 in borrowings during the period, down from CNY 862,440,000.00 in the previous year[21]. Operational Metrics - The weighted average return on equity for Q3 2024 was 1.83%, an increase of 0.19 percentage points compared to the previous quarter[3]. - Research and development expenses for the first three quarters of 2024 were ¥297,141,310.80, compared to ¥291,314,885.11 in 2023, indicating an increase of about 2.00%[18]. - The company reported a decrease in management expenses to ¥301,150,902.47 from ¥351,188,573.97, reflecting a reduction of approximately 14.26%[18]. - The company experienced a decline in cash received from sales of goods and services, impacting the cash flow from operating activities negatively[6]. - The company reported a decrease in revenue from sales of goods and services to CNY 6,962,340,927.85, compared to CNY 7,428,162,090.93 in the same period last year[20]. Asset Composition - Total current assets as of September 30, 2024, amounted to ¥9,367,034,360.25, a decrease from ¥9,454,331,945.33 at the end of 2023, reflecting a decline of approximately 0.92%[12]. - Cash and cash equivalents decreased to ¥2,474,624,687.68 from ¥3,188,296,441.67, representing a decline of about 22.3%[12]. - Accounts receivable increased to ¥2,031,717,938.62 from ¥1,694,832,478.74, marking an increase of approximately 19.9%[13]. - Inventory decreased to ¥3,441,900,783.28 from ¥3,555,786,774.42, indicating a decline of about 3.2%[13]. - Long-term equity investments decreased to ¥1,488,841,800.85 from ¥1,633,724,381.31, reflecting a decline of approximately 8.8%[13]. - Non-current assets totaled ¥6,022,185,854.76, down from ¥6,135,997,829.90, indicating a decrease of about 1.85%[13]. - The company reported a significant increase in other receivables, which rose to ¥605,410,991.25 from ¥238,494,581.70, an increase of approximately 153.5%[13]. Legal and Regulatory - The company reached a settlement with 3M Innovation Co., Ltd., agreeing to pay a settlement amount of ¥20 million related to patent disputes[11]. - The company has not disclosed any related party relationships among the top ten shareholders[10]. - There were no changes in the participation of major shareholders in margin trading and securities lending activities compared to the previous period[10]. Future Outlook - Future outlook includes continued focus on market expansion and potential new product development, although specific figures were not disclosed in the report[18].

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-038 山东新华医疗器械股份有限公司 1、产品名称：鼻窦镜 2、注册证编号：鲁械注准 20242060939 3、注册人名称：新华手术器械有限公司 4、注册人住所：淄博高新区泰美路 7 号 5、生产地址：淄博高新区泰美路 7 号 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公 司新华手术器械有限公司于近日收到山东省药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 M 型：175Φ2.7,0°、175Φ2.7,30°、175Φ4,0°、175Φ4,30°、175Φ 4,70° 8、适用范围：用于在鼻窦观察成像。 9、批准日期：2024 年 10 月 20 日 10、有效期至：2029 年 10 月 19 日 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至 目前，国内同行业有 ...

北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 山 东 新 华 医 疗 器 械 股 份 有 限 公 司 回 购 注 销 2021 年 限 制 性 股 票 激 励 计 划 部 分 限 制 性 股 票 及 调 整 回 购 价 格 之 法 律 意 见 书 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 君致（ 法 ）字[2024]373 号 1 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 回购注销 2021 年限制性股票激励计划部分限制性股票 及调整回购价格之法律意见书 君致法字 2024373 号 致：山东新华医疗器械 ...

证券代码：600587 证券简称：新华医疗 公告编号：临2024-037 山东新华医疗器械股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：根据公司《2021 年限制性股票激励计划（草案）》（以下 简称"《激励计划》"）的相关规定，原授予限制性股票的激励对象崔权离职， 不再符合激励条件，公司拟对该激励对象已获授但尚未解除限售的限制性股票合 计 8,667 股进行回购并注销。 本次注销股份的有关情况 本次回购注销限制性股票涉及崔权 1 人，合计拟回购注销限制性股票 8,667 股，公司已足额支付股份回购款项；本次回购注销完成后，剩余股权激励限制性 股票 463.1427 万股。 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 8,667 | 8,667 | 2024 | 年 | 10 | 月 | 25 | ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-036 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 型号：C、D 规格：尺寸：16×16、20×20、25×26.5、25×50、25×60、98×10、98× 12、98×14、98×16、98×18、98×20、98×22、98×25、98×30 颜色：A1，A2，A3，A3.5，A4，B1，B2，B3，B4，C1，C2，C3，C4，D2， D3，D4，1M1，1M2，2L1.5，2L2.5，2M1，2M2，2M3，2R1.5，2R2.5，3L1.5， 3L2.5，3M1，3M2，3M3，3R1.5，3R2.5，4L1.5，4L2.5，4M1，4M2，4M3， 4R1.5，4R2.5，5M1，5M2，5M3，0M1,0M2,0 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-035 山东新华医疗器械股份有限公司 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公 司上海天清生物材料有限公司于近日收到国家药品监督管理局颁发的《中华人民 共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：可吸收性外科缝线 2、注册证编号：国械注准 20243021789 3、注册人名称：上海天清生物材料有限公司 4、注册人住所：上海市松江区文翔路 419 号 5、生产地址：上海市松江区文翔路 419 号 6、结构及组成：可吸收外科缝线由缝线和缝合针（可选）组成，分带针型 （带单/双针）和不带针型。缝线经熔纺加工后表面切割出分布均匀的螺旋形单/ 双向倒刺。缝线材质：聚对二氧环己酮（PDO），单股、无涂层；缝合针材质： 302 不锈钢（化学牌号：12Cr18Ni9），含硅涂层；缝线染色：紫色，染料：D&C 紫色二号（CAS 号:81-48-1）。产品经环氧乙烷灭菌，一次性使用。 关于子公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 ...

山东新华医疗器械股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 10 月 18 日(星期五) 上午 11:00-12:00 投资者可于 2024 年 10 月 11 日(星期五) 至 10 月 17 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-034 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 10 月 18 日上午 11:00- 12:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company reported a revenue of 5.187 billion yuan for the first half of 2024, reflecting a year-over-year growth of 2.24%, and a net profit attributable to shareholders of 484 million yuan, up 5.57% year-over-year [2]. - The medical device business is under pressure, but profitability continues to improve, with a gross margin of 26.65% and a net profit margin of 9.60% for the first half of 2024 [2]. - The company is focusing on cost reduction and efficiency improvements, leading to a significant enhancement in profitability metrics [2]. Revenue and Profit Forecast - The company is projected to achieve total revenues of 10.802 billion yuan, 11.671 billion yuan, and 12.637 billion yuan for the years 2024, 2025, and 2026, respectively, with growth rates of 7.89%, 8.05%, and 8.27% [3][4]. - Net profit attributable to shareholders is expected to reach 783 million yuan, 940 million yuan, and 1.162 billion yuan for the same years, with growth rates of 19.72%, 20.08%, and 23.62% [3][4]. Financial Metrics - The report highlights a projected PE ratio of 12x for 2024, 10x for 2025, and 8x for 2026, indicating a favorable valuation compared to comparable companies in the medical device sector [3]. - The company’s gross margin is expected to improve gradually, reaching 28.82% by 2026 [4]. Business Segment Performance - The medical device segment generated revenue of 1.887 billion yuan in the first half of 2024, down 2.55% year-over-year, while the pharmaceutical equipment segment saw revenue of 1.092 billion yuan, up 4.38% year-over-year [2]. - The company is adapting to market conditions by focusing on consumables and small-scale sterilization products, which are expected to drive growth in the second half of the year [2].

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-033 山东新华医疗器械股份有限公司 关于公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情 况如下： 一、医疗器械注册证的具体情况 1、产品名称： X 射线计算机体层摄影设备 2、注册证编号：国械注准 20243061705 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：该产品由扫描架、扫描床、控制台、电源柜和选配件组成， 其中扫描架包含高压发生器、X 射线管组件、探测器、准直器，控制台含主机和 显示器，选配件包括头部延长板和头托。 7、型号、规格：XHCT-16iM 8、适用范围：该产品用于常规临床 CT 检查，可为放射治疗计划提供图像数 据。 9、批准日期 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 25 yuan, compared to the current price of 16.62 yuan [1]. Core Views - The medical device sector is experiencing temporary pressure, but the company has optimized its expense ratio, leading to an improvement in net profit margin [1]. - The company reported a revenue of 5.187 billion yuan (+2.24%) and a net profit of 484 million yuan (+5.57%) for the first half of 2024 [1]. - The decline in medical device revenue is attributed to compliance actions and delayed procurement needs from hospitals [1]. - The international contract amount for pharmaceutical equipment has seen rapid growth, with domestic revenue at 5.082 billion yuan (+2.20%) and overseas revenue at 105 million yuan (+4.15%) [1]. - The company's gross margin slightly decreased to 26.65%, with the medical device segment's gross margin increasing to 43.29% despite a revenue decline [1]. - The overall expense ratio has improved, with a sales expense ratio of 7.88% (-0.78 percentage points) and a management expense ratio of 3.81% (-0.90 percentage points) [1]. - The company expects a gradual recovery in bidding activities in the second half of the year, maintaining profit forecasts for 2024-2026 [1]. Financial Summary - For the first half of 2024, the company reported a gross margin of 26.65%, with the medical device segment's gross margin at 43.29% and the pharmaceutical equipment segment's gross margin at 27.12% [1]. - The projected net profit for 2024-2026 is 830 million yuan, 1.04 billion yuan, and 1.28 billion yuan, respectively, with year-on-year growth rates of 27.3%, 24.7%, and 23.5% [2]. - The earnings per share (EPS) are expected to be 1.37 yuan, 1.71 yuan, and 2.11 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (PE) ratios of 12, 10, and 8 [2].